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Introduction
Appropriate phosphorylation of signal
transducer and activator of transcription
（STAT） transcriptional factors, down-stream
mediators of Janus kinases（JAKs）, regulates
expression of various genes during normal
hematopoiesis. Reflecting dysregulation of
the JAK-STAT pathway, constitutive activa-
tion of STAT３ and STAT５ is frequently
detected in hematopoietic malignancies１）. In
particular, the JAK２V６１７F hyperactive muta-
tion, which leads to hyperphosphorylation of
STAT５，was recently found to occur in most
patients with myeloproliferative neoplasms
（MPNs）２）: mainly polycythemia vera （PV）,
essential thrombocythemia（ET）and primary
myelofibrosis（PMF）. Recent studies also in-
dicate that the expression levels of the JAK２
V６１７F mutant may influence disease type
selection３）. We have therefore been investi-
gating the possibility that monitoring the level
of STAT５A phosphorylation could be helpful
for the diagnosis, treatment and follow-up of
MPNs.
Multicolor flow cytometry is a powerful
diagnostic tool able to detect and separate
abnormal cell populations from normal blood
cells, even when the abnormal population is
very small. And thanks to recent progress in
intracellular staining methods, one can now
use this method to detect phosphorylated
proteins at the single cell level４）. Standard
detection protocols are generally provided by
the manufacturer ; however, whole peripheral
blood contains cells of different lineage that
show differing degrees of membrane stability
during fixation, and each lineage-specific
antigen and phosphorylated protein has a
different tolerance for fixation. Therefore,
the protocol used to stain whole blood for
detection of both intracellular phosphorylated
proteins and surface lineage makers in the
same cells should be optimized for each
experiment.
Methods, results and discussion
To optimize staining of phosphorylated
STAT５A along with a lineage marker, we used
Jurkat cells transduced with a retroviral vector
encoding STAT５A１*６５）（Fig. 1）. We first deter-
mined the optimal fixation, permeabilization and
staining conditions for detecting FLAG on the
intracellular STAT５A１*６ using flow cytometry
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（MoFlo, Beckman-Coulter, Brea, CA） with an
anti-FLAG antibody （AD００５９F, Perkin Elmer
Japan, Kanagawa, Japan）. By comparing several
conventional methods, we determined the best
conditions for detecting intracellular molecules to
be fixation with prewarmed BD Phosflow Fix
Buffer I（BD Japan, Tokyo, Japan）for１０min at
３７℃, followed by permeabilization with BD
Phosflow Perm Buffer III（BD Japan）for３０min
at４℃.
We confirmed our ability to detect intracellu-
lar STAT５A１*６ under the selected conditions
using peripheral blood cells from a progressive
MPN model mouse６）. Establishment of the MPN
mouse was described previously. Briefly, highly
purified HSCs （CD３４-KSL）７） from C５７BL／６J
mouse （B６, CREA Japan, Tokyo, Japan） bone
marrow were transduced using a retroviral vector
encoding STAT５A１*６, and then transplanted into
a lethally irradiated B６ mouse. Six weeks later,
Fig. 1A Schematic presentation of the retroviral vector encoding STAT５A１*６（GCDNsamSTAT５A１*６ I／
G）. Expression of STAT５A１*６ is driven by the retroviral promoter long terminal repeat（LTR）.
SD, splicing donor ; SA, splicing acceptor ; ψ＋, packaging signal ; IRES, internal ribosomal entry
site ; GFP, green fluorescent protein.
Fig. 1B Schematic presentation of the experimental design. Highly purified hematopoietic stem cells（CD
３４-KSL HSC） were obtained from C５７B／６（ly５．１） bone marrow and transduced with
GCDNsamSTAT５A１*６ I／G or control vector. The genetically modified HSCs were then
transplanted to９５０ cGy-irradiated C５７B／６（Ly５．２）recipient mice along with７．５x１０５ whole bone
marrow cells from a C５７B／６（Ly５．１／Ly５．２）mouse as rescue cells. Peripheral blood from the
recipient mouse was analysed６weeks after transplantation. The genetically modified donor cells,
recipient cells and rescue cells could be identified based on their expression of CD４５．１（Ly５．１）and
／or CD４５．２（Ly５．２）.
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peripheral blood cells were collected for flow
cytometric analysis （Fig. 2）. After lysing the
erythrocytes by incubating the cells in１ml of１４０
mM NH４CL for１５min at room temperature, the
remaining white blood cells（～１x１０６ cells）were
fixed and permeabilized under the aforementioned
conditions. To block nonspecific staining of intra-
cellular molecules by the specific antibodies,５０μl
of １０x diluted affinity-purified mouse IgG１, k
（eBioscience, San Diego, CA）was added to the
Fig. 2A Representative result of intracellular STAT５A１*６
and surface lineage-antigen staining in peripheral
blood cells from a MPN mouse. Samples of whole
blood from a MPN mouse were processed as summa-
rized in Table １. Intracellular STAT５A１*６ was
detected only in myeloid cells from the MPN mouse,
which is indicative of the myeloid origin of the
disease.
Fig. 2B Human ESC-derived hematopoietic cells８） were
transduced using control vector or GCDNsam STAT５
A１*６I／G, then cultured in the presence of EPO, SCF
and TPO. Cells were harvested on day１０of culture
and processed for intracellular phosphoSTAT５A and
glycophorin A double staining using anti-phospho
STAT５A（Y６９４）, anti-glycophorin A and anti-CD４５
antibodies. Forced EPO-induced STAT５A phospho-
rylation has been detected in glycophorin A-positive
cells. The numbers in the plot indicate the percent-
ages of cells in the quadrants.
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test cells and incubated for３０min at４℃ prior to
addition of the specific antibodies. This enabled
efficient staining of intracellular STAT５A１*６.
Because each surface antigen and antibody
had a different tolerance for the fixation and
permeabilization protocol, we next identified the
optimal staining time for surface antigens. Anti-
bodies for myeloid（anti-mouse Gr-１ Pacific Blue,
１０８４３０, Biolegend Japan, Tokyo, Japan ; anti-mouse
Mac-１ Pacific Blue,１０１２２４, Biolegend Japan）and
lymphoid（anti-mouse B２２０ APC-Cy７,２５-０４５２-８２,
eBioscience ; anti-mouse CD４ APC-Cy７,１００４１４,
Biolegend Japan ; anti-mouse CD８a APC-Alexa
Fluor ７８０,４７-００８１-８２, eBioscience） antigens
showed measurable intensity, even when added
before fixation and permeabilization. By contrast,
anti-CD４５ antibodies（anti-mouse CD４５．１ PE-Cy７,
２５-０４５３-８２, eBioscience ; anti-mouse CD４５．２ PE,
１２-０４５４-８３, eBioscience）lost their affinity for CD
４５ antigen under the same conditions. In that
context, we labeled using a double staining
method in which myeloid and lymphoid antigens
were labeled before fixation and permeabilization,
while CD４５ and intracellular molecules were
labeled afterward. The optimized staining
protocol is summarized in Table 1. Using this
approach, we have been able to detect myeloid
cell-specific expression of STAT５A１*６ in MPN
mice（Fig. 2A）, which is indicative of the myeloid
cell origin of MPN.
To determine whether this staining protocol
can be applied to human cells, we checked for
phosphorylated STAT５A in STAT５A１*６－
transduced human ESC（khESC３, kindly provided
from Dr. Suemori of Kyoto Univ.）－derived blood
cells （anti-phospho STAT５ Alexa Fluor ６４７
antibody, BD Japan ; anti-human CD４５ PE-Cy７
antibody, BD Japan ; anti-human Glycophorin A
Pacific Blue antibody, eBioscience）. As indicated
in Fig. 2B, among ESC-derived cells transduced
with STAT５A１*６, we were able to detect
aberrantly strong phosphorylation of STAT５A in
Glycophorin A-expressing erythroid cells using
multicolor staining（Shimizu T et al., in submis-
sion）.
In conclusion, we have optimized a method
Table 1 Detection procedure for lineage-specific STAT5A phosphorylation by multi-color
flow cytometry using peripheral blood cells
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for intracellular molecular staining together with
multicolor surface antigen staining of peripheral
blood cells from MPN mice. Further analysis of
MPN patients using this method would be
expected to clarify the relationship between
STAT５A phosphorylation and MPN disease type
selection and progression.
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骨髄増殖性疾患への診療応用を目標としたマルチカラーフローサイトメトリーによる
細胞内リン酸化 STAT５A分子と表面分化抗原との同時染色法の開発
清水 崇史*，中川 英，入口 翔一，金子 新，中内 啓光
*東京大学医科学研究所 幹細胞治療研究センター 幹細胞治療分野
古典的な骨髄増殖性疾患（classical myeloproliferative neoplasm ; classical MPN）である真性多血
症（polycythemia vera ; PV）の大多数や本態性血小板血症（Essential thrombocythemia ; ET）な
らびに原発性骨髄線維症（Primary myelofibrosis ; PMF）の一部において JAK２遺伝子変異が報告
されている．当研究室では JAK２下流因子の一つである STAT５Aの活性型（STAT５A１*６）を造血
幹細胞に遺伝子導入して骨髄移植を行い，MPNモデルマウスの作製に成功している（Kato Y et al.,
２００５, JEM）．本研究ではフローサイトメトリー（FCM）を用いてMPNモデルマウス末梢血中の各
種細胞群における STAT５A１*６発現解析ならびにヒト血液細胞内におけるリン酸化 STAT５A発現解
析を試みた．
細胞内蛋白質である STAT５Aの解析は，細胞固定，膜透過処理後に染色する必要がある．我々は
Phosflow用試薬（BD社）を用い，細胞固定，膜透過処理及び染色条件の最適化を行った結果，MPN
モデルマウス末梢血において，種々の分化抗原マーカーを同時染色しつつ，STAT５A１*６を定量的に
解析することに成功し，同モデルマウスでは末梢血顆粒球分画特異的に活性化 STAT５Aの強発現が
見られることが明らかになった．また，本法を用いてヒト末梢血単核球やヒト胚性幹細胞由来血液細
胞を解析した結果，活性化 STAT５Aを表面抗原と同時染色することが可能であった．末梢血におけ
る分画別活性化 STAT５A定量が，MPN診療に貢献できる可能性を示唆している．
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